Logo

atrial fibrillation

Helix Showcases New Population Genomics Method in Cardiomyopathy Risk Study
Premium

Using a "sliding power window" method, the company found certain gene variant carriers with atrial fibrillation at higher risk for cardiomyopathies.

Clinical Polygenic Risk Assay, Reporting Pipeline Shows Promise for Multiple Conditions
Premium

Researchers developed assays to assess PRSs for six common conditions, along with methods for sharing the results with doctors and patients.

International Heart Rhythm Societies Set Out Recommendations on Genetic Testing for Cardiac Diseases

The consensus statement, published this week, should help to guide decision-making around genetic testing for a variety of cardiac conditions.

Cardiometabolic Disease Shows Ties to Depressive Mood, Irrespective of Genetic Risk

Researchers saw an uptick in coronary artery disease, atrial fibrillation, and type 2 diabetes in individuals with frequent depressed mood across polygenic risk scores.

IBM Watson, Broad Institute Expand Collaboration Into Heart Disease

IBM and the Broad Institute will codevelop algorithms to apply artificial intelligence to predict cardiovascular risk from genomic and clinical data.

Nov 7, 2018

Scripps-Nvidia Partnership Melding Genomics, Sensor Data
Premium

Aug 13, 2018

Broad Institute, Mass General Team Develops Polygenic Risk Scores for Five Common Diseases

Jul 30, 2018

Massive Atrial Fibrillation GWAS Leads to 80 New Risk Loci

Jun 27, 2018

Lifestyle, Genetics Independently Predict Cardiovascular Disease, Diabetes Risk

Mar 21, 2018

Addition of Genetic Risk Score Improves Chances of IDing Atrial Fibrillation Patients, Study Finds
Premium

Dec 28, 2017

Atrial Fibrillation GWAS Provides Clues to Heart Condition

Nov 27, 2017

European Consortium Aims to Deliver New Tests, Therapies for Cardiovascular Diseases
Premium

Apr 17, 2017

New Variants Linked to Atrial Fibrillation Risk

Jun 22, 2016

Single SNP Mediates Some Differences in Atrial Fibrillation Risk Between Europeans, African Americans

Apr 10, 2015

ARCA Stays Committed to Developing Heart Failure Rx with PGx Strategy despite Setbacks
Premium

Mar 10, 2015

Study Provides 'Strong Evidence' Backing Warfarin Initiation PGx Testing; Adoption Impact Unclear
Premium

Apr 16, 2014

Celera Researchers Investigating Genetic Risk Signature to Predict Atrial Fibrillation
Premium

Mar 6, 2014

Rosetta Data Links microRNA-150 to Atrial Fibrillation in Heart Failure Patients
Premium

Jan 8, 2014

FDA Accepts LabCorp's IDE Application for Atrial Fibrillation CDx

Dec 4, 2013

Two Conflicting Prospective, RCTs on Warfarin PGx Provide No Definitive Guidance to Physicians
Premium

Oct 24, 2012

Study Suggests Two-Gene Combo Predicts Spectrum of Response to ARCA's Beta Blocker Gencaro
Premium

Dec 14, 2011

FDA Looks into Pradaxa Bleeding Risk; What Does it Mean for PGx-Guided Warfarin Dosing?
Premium

Oct 3, 2011

Warnex to Distribute DeCode Genetics Tests in Canada

Mar 15, 2011

Xention to Study Biomarkers for AF Network

Oct 27, 2010

When Might Warfarin PGx Be Better Than Pradaxa? Stakeholders Weigh In
Premium

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.